THE METABOLIC SYNDROME: A THREAT FOR BOTH FLIGHT PERSONNEL AND PASSENGERS


Felice STROLLO

ESAM Secretary General
Diabetes Unit - San Raffaele Institute - Rome, Italy

Abdominal obesity and metabolic syndrome

Jean-Pierre Després & Isabelle Lemieux *Nature* 444: 881-87, 2006.


Abdominal obesity, the most prevalent manifestation of the MS, is a marker of 'dysfunctional adipose tissue', and is of central importance in clinical diagnosis.




Visceral Adipose Tissue (VAT)

Subcutaneous A. T. (SAT)


Intra-abdominal adiposity and glucose metabolism



IAA: intra-abdominal adiposity Significantly different from ¹non-obese, ²obese with low intra-abdominal adiposity levels



CRITERIA	ATP III (2006): at least 3 criteria
OBESITY	Waist circumference men ≥ 102 cm; women ≥ 88 cm
DYSLIPIDEMIA	 a) Triglicerides ≥ 150 mg/dl and/or therapy b) HDL-C men <40 mg/dl; women <50 mg/dl and/or therapy
HYPERTENSION	≥ 130/85 mmHg. and/or therapy
GLYCEMIA	≥ 100 mg/dl. and/or therapy
INSULIN - RESISTANCE	No marker




A cluster of INSULIN-RESISTANCE-RELATED


CHANGES in METABOLISM (lipids + glucose) and

VESSELS (hypertension + trombophylia) leading to

INCREASED CV RISK




Metabolic Syndrome: prognosis



PASSENGER HEALTH: MOSTLY IGNORED

- when combined with
 - smoking and
 - o aging
- the MS is a risk factor for well known threats during long-haul flights:
 - venous thrombo-embolism,
 - o arterial thrombosis.







Figure 1. Prevalence of the metabolic syndrome in various countries according to the ATP III definition. (Adapted from Gu D et al. Lancet 2005;365:1398–1405; Eckel et al. Lancet. 2005;365: 1415–28; and Ford E et al. Diabetes Care. 2004;27:2444–9.)


Prevalence of the NCEP Metabolic Syndrome: NHANES III by Age



Mean = 25-30%

 $>60 \text{ yrs} \approx 40\%$

Ford ES et al. JAMA 2002;287:356-359.




WHAT ABOUT THE MILITARY AIRCREW?

- cardiovascular disease and diabetes mellitus negatively influence quality of life
- they are also disabling for aging military aircrew;
- among Royal Jordanian Air Force pilots its prevalence was shown to be the same as in the general population;
- this raises medical concern, since military pilots are generally regarded as healthy and fit, somehow "forever young" after their first evaluation.

Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease¹⁻³

Richard J Johnson, Mark S Segal, Yuri Sautin, Takahiko Nakagawa, Daniel I Feig, Duk-Hee Kang, Michael S Gersch, Steven Benner, and Laura G Sánchez-Lozada




Am J Clin Nutr 2007;86:899-906.

- Residues of 8 Persistent Organic Pollutants (POPs) in adipose tissue samples from 387 people in Granada province (Spain, 2003 - 2004).
- β-HCH and HCB = independently associated with increased metabolic risk (ORs =1.17, p<0.05) also after a 10-year follow-up (OR =1.25, p<0.05).

β-HCH = β-hexachlorocyclohexane (cotton plant pesticide)

HCB = hexachlorobenzene (wheat fungicide + byproduct of industrial chemicals)



These POPs might be partly responsible for the morbidity risk traditionally attributed to age and obesity.



Influence of Age on the Relationship between Alcohol Consumption and Metabolic Syndrome

Ichiro Wakabayashi

Table 3. Comparison of prevalence of each risk factor for atherosclerosis or metabolic syndrome (MetS) among nondrinker, light drinker, heavy drinker and very heavy drinker subgroups of the younger (Y) and older (O) subject groups

Gerontology 2012;58:24-31


Variable Y: 35-45 yrs; n = 1390		Overall		Drinker group							
	O: ≥ 65 yrs; n = 1390			none	drinker	light		heavy	у	very l	heavy
Large waist c	ircumference, %	Y: O:	36.3 44.4 ^{††}	Y: O:	40.0 44.4	Y: O:	31.2* 43.7	Y: O:	34.8 45.0	Y: O:	36.3 43.6
High blood p	pressure, %	Y: O:	45.5 76.8 ⁺⁺	Y: O:	39.8 69.3	Y: O:	43.7 75.8	Y: O:	47.6* 80.0**	Y: O:	55.4** 88.2**
Low HDL ch	olesterol, %	Y: O:	8.6 13.2 ^{††}	Y: O:	15.6 22.8	Y: O:	5.6** 12.1**	Y: O:	4.7** 7.4**	Y: O:	4.4** 5.9**
High triglyce	erides, %	Y: O:	32.7 26.0 ^{††}	Y: O:	32.8 28.8	Y: O:	24.7* 20.9*	Y: O:	32.5 24.5	Y: O:	41.7* 28.4
High HbA ₁₀	%	Y: O:	3.8 14.5 ^{††}	Y: O:	6.8 15.6	Y: O:	0.5** 16.7	Y: O:	2.0** 14.9	Y: O:	4.4 8.3*
MetS by IDF	, %	Y: O:	13.7 23.3 ^{††}	Y: O:	16.0 25.5	Y: O:	9.8* 22.8	Y: O:	11.5* 22.3	Y: O:	17.6 21.1
MetS by NCI	EP-ATP III, %	Y: O:	13.8 24.7 ⁺⁺	Y: O:	16.2 27.2	Y: O:	9.8* 23.4	Y: O:	11.7* 23.7	Y: O:	17.6 23.0

The prevalence of each risk factor for atherosclerosis or metabolic syndrome is shown. Light drinkers: <22 g ethanol/day; heavy drinkers: ≥22 and <44 g ethanol/day; very heavy drinkers: ≥44 g ethanol/day. Marks denote significant differences from the nondrinker subgroup (* p < 0.05; ** p < 0.01) and the younger group (†† p < 0.01).

ASSOCIATED PATHOLOGIC CONDITIONS:

- steato-hepatitis
- male hypogonadism
- osteopenia
- depression








TABLE 3. **ABCDE Approach for Treating the Metabolic Syndrome**^{a.b}

Make metabolic syndrome diagnosis, *ICD-9* code 277.7 Assessment Calculate Framingham risk score All patients with >6% 10-y Framingham risk Aspirin Blood pressure control Goal blood pressure is <130/80 mm Hg if intermediate risk (≥6% 10-y risk) В First-line therapy: ACEI or ARB β-Blockers, thiazide diuretics may increase risk of diabetes C Cholesterol management First target: LDL-C Statins to achieve LDL-C <100 mg/dL in high-risk, <130 mg/dL in intermediate-risk (≥6% 10-y risk) patients per the NCEP ATP III Statin intensification Second target: non-HDL-C Fenofibrate to achieve target non–HDL-C <130 mg/dL in high-risk, <160 mg/dL in intermediate-risk patients per NCEP ATP III Consider omega-3 fatty acids Third target: HDL-C Long-acting niacin, although insufficient evidence for wide use of niacin at this time due to concern for increased glucose intolerance Diabetes prevention Intensive lifestyle modification for all patients; pharmacotherapy is second line D Metformin Consider pioglitazone Diet Weight loss Mediterranean diet: increase omega-3 fatty acids, fruits, vegetables, fiber, nuts Low glycemic load diet Exercise Daily vigorous activity Е Recommend use of pedometer with goal >10,000 steps/d

METABOLIC SYNDROME AND RELATED DISORDERS Volume 8, Number 4, 2010 © Mary Ann Liebert, Inc. Pp. 317–322 DOI: 10.1089/met.2009.0090

Walking in Old Age and Development of Metabolic Syndrome: The Health, Aging, and Body Composition Study

Matthew J. Peterson, Ph.D.,¹⁻³ Miriam C. Morey, Ph.D.,^{1,3} Carol Giuliani, Ph.D.,² Carl F. Pieper, Dr.P.H.,^{1,3} Kelly R. Evenson, Ph.D.,⁴ Vicki Mercer, Ph.D.,² Marjolein Visser, Ph.D.,⁵ Jennifer S. Brach, Ph.D., P.T., G.C.S.,⁶ Stephen B. Kritchevsky, Ph.D.,⁷ Bret H. Goodpaster, Ph.D.,⁸ Susan Rubin, M.P.H.,⁹ Suzanne Satterfield, M.D., Dr.P.H.,¹⁰ and Eleanor M. Simonsick, Ph.D.,^{11,12} for the Health ABC Study


N = 1863 sigjects Age = 70–79 years Follow-up = 5 years Exercise self-report

- sustained low (<150 min/wk)
- decreased (from >150 to <150 min/wk)
- increased (from <150 to >150 min/wk)
- sustained high (>150 min/wk)

`	Metabolic	Number of metabolic syndrome risk factors ^b					
	Model 1 ^c	Model 2 ^d	Mode	el 1 ^d	Model 2 ^e		
Walking group	OR (95% CI)	OR (95% CI)	β	p	β	p	
Sustained low	1.00	1.00	0		0		
Decreased	0.95 (0.71-1.26)	0.97 (0.73-1.30)	-0.06	0.37	-0.07	0.29	
Increased	1.05 (0.69–1.61)	1.04 (0.67–1.60)	-0.08	0.42	0.02	0.84	
Sustained high	0.59 (0.38-0.89)	0.61 (0.40-0.93)	-0.23	0.007	-0.16	0.04	

^dAdjusted for year 1 body weight, race, education, number of diagnoses, heart disease, and year 1 min/week in high-intensity exercise.

^eAdjusted for year 1 body weight, race, education, number of diagnoses, heart disease, baseline min/week in high-intensity exercise, and number of metabolic syndrome factors present at year 1.



2008 US PHYSICAL ACTIVITY GUIDELINES

RESISTANCE EXERCISE ≥2 d/wk moderate-high intensity, all major muscle groups

AEROBIC EXERCISE ≥500 metabolic equivalent min/wk (≥8.5 MET/h/wk)

	No. (%) of	No. of	Adjusted hazard ratio (95% CI)					
Variable	participants	MetS cases	Model I ^b	Model 2 ^c	Model 3 ^d			
Weekly minutes of re	esistance exercise							
0	4633 (62)	816	1.00 [Reference]	1.00 [Reference]	I.00 [Reference]			
1-59	670 (9)	80	0.62 (0.49-0.78)	0.69 (0.55-0.86)	0.71 (0.56-0.89)			
Recommended resist	ance exercise		, i	,	,			
No (<2 d/wk)	4839 (65)	838	I.00 [Reference]	1.00 [Reference]	I.00 [Reference]			
Yes (≥2 d/wk)	2579 (35)	309	0.71 (0.62-0.80)	0.81 (0.71-0.92)	0.83 (0.73-0.96)			
103 (<u>></u> 2 0/WK)	2377 (33)	307	0.71 (0.02-0.00)	0.01 (0.71-0.72)	0.03 (0.73-0.70)			

parental history of cardiovascular disease, hypertension, and diabetes.

^dAdjusted for model 2 plus aerobic exercise (inactive, insufficient, medium, and high).

Bakker EA et al. Mayo Clin Proc. 2017; http://dx.doi.org/10.1016/j.mayocp.2017.02.018

POSSIBLE COUNTERMEASURES FOR FLIGHT PERSONNEL

Both pilots and flight attendants should be provided with:

- continuous structured nutritional education and
- regular exercise counseling and monitoring

POSSIBLE COUNTERMEASURES FOR PASSENGERS

- Need to prevent life-threatening CV events during the travel, implying
 - huge emotionally relevant consequences
 - o related socio-economic burden
- for:
 - flight companies
 - the society itself.
- Strong actions should be urgently taken to
 - limit weight gain and
 - identify those at risk for or affected by the MetS.

HOW?

Frequent travellers might be the object of extensive / hammering institutional information campaigns through

- the media
- travel agencies and
- airport access points.